0|chunk|Potential Therapeutic Agents for Feline Calicivirus Infection

1|chunk|Feline calicivirus (FCV) is a major cause of upper respiratory tract disease in cats, with widespread distribution in the feline population. Recently, virulent systemic diseases caused by FCV infection has been associated with mortality rates up to 50%. Currently, there are no direct-acting antivirals approved for the treatment of FCV infection. Here, we tested 15 compounds from different antiviral classes against FCV using in vitro protein and cell culture assays. After the expression of FCV protease-polymerase protein, we established two in vitro assays to assess the inhibitory activity of compounds directly against the FCV protease or polymerase. Using this recombinant enzyme, we identified quercetagetin and PPNDS as inhibitors of FCV polymerase activity (IC 50 values of 2.8 M and 2.7 M, respectively). We also demonstrate the inhibition of FCV protease activity by GC376 (IC 50 of 18 M). Using cell culture assays, PPNDS, quercetagetin and GC376 did not display antivirals effects, however, we identified nitazoxanide and 2 -C-methylcytidine (2CMC) as potent inhibitors of FCV replication, with EC 50 values in the low micromolar range (0.6 M and 2.5 M, respectively). In conclusion, we established two in vitro assays that will accelerate the research for FCV antivirals and can be used for the high-throughput screening of direct-acting antivirals.
1	20	23 FCV	Chemical	CHEBI_4974
1	188	191 FCV	Chemical	CHEBI_4974
1	292	302 antivirals	Chemical	CHEBI_22587
1	333	336 FCV	Chemical	CHEBI_4974
1	392	401 antiviral	Chemical	CHEBI_22587
1	418	421 FCV	Chemical	CHEBI_4974
1	437	444 protein	Chemical	CHEBI_16541
1	494	497 FCV	Chemical	CHEBI_4974
1	518	525 protein	Chemical	CHEBI_16541
1	630	633 FCV	Chemical	CHEBI_4974
1	703	716 quercetagetin	Chemical	CHEBI_8695
1	730	740 inhibitors	Chemical	CHEBI_35222
1	744	747 FCV	Chemical	CHEBI_4974
1	857	860 FCV	Chemical	CHEBI_4974
1	940	953 quercetagetin	Chemical	CHEBI_8695
1	980	990 antivirals	Chemical	CHEBI_22587
1	1077	1087 inhibitors	Chemical	CHEBI_35222
1	1091	1094 FCV	Chemical	CHEBI_4974
1	1277	1280 FCV	Chemical	CHEBI_4974
1	1281	1291 antivirals	Chemical	CHEBI_22587
1	1359	1369 antivirals	Chemical	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_4974	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_4974	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_4974	CHEBI_8695
1	CHEBI-CHEBI	CHEBI_4974	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_16541
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_8695
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_16541	CHEBI_8695
1	CHEBI-CHEBI	CHEBI_16541	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_8695	CHEBI_35222

2|chunk|The single-stranded, positive-sense FCV RNA genome (~7.7 kb) is VPg linked, polyadenylated, and includes three open reading frames (ORFs) [16] . ORF1 encodes non-structural proteins, including the 3C-like protease and 3D-like polymerase, ORF2 encodes the major capsid protein and ORF3 encodes a minor protein component of the virion [17] . Wei et al. [18] have demonstrated that the active form of the FCV polymerase is the bifunctional protease-polymerase (Pro-Pol) protein. FCV shows a high level of genetic diversity due to the lack of proofreading and the low fidelity of the viral polymerase, and genome recombination between different FCV strains during coinfections [4, 19, 20] . The phylogenetic classification of FCV strains, based on ORF2 nucleotide sequences, have demonstrated the circulation of a single genogroup (GI) around the globe, with the exception of Japan which has additional circulating strains that belong to a second genogroup (GII) [21] [22] [23] .
2	36	39 FCV	Chemical	CHEBI_4974
2	40	43 RNA	Chemical	CHEBI_33697
2	173	181 proteins	Chemical	CHEBI_36080
2	268	275 protein	Chemical	CHEBI_16541
2	301	308 protein	Chemical	CHEBI_16541
2	402	405 FCV	Chemical	CHEBI_4974
2	467	474 protein	Chemical	CHEBI_16541
2	476	479 FCV	Chemical	CHEBI_4974
2	641	644 FCV	Chemical	CHEBI_4974
2	722	725 FCV	Chemical	CHEBI_4974
2	749	759 nucleotide	Chemical	CHEBI_36976
2	CHEBI-CHEBI	CHEBI_4974	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_4974	CHEBI_36080
2	CHEBI-CHEBI	CHEBI_4974	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_4974	CHEBI_36976
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_36080
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_36976
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_36080	CHEBI_36976
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_36976

3|chunk|Live-attenuated and inactivated vaccines against FCV have been available for over 40 years, using different FCV strains in monovalent or bivalent compositions [24] . Current vaccines do not prevent infection, viral shedding, or the development of FCV-VSD, but can reduce or even prevent clinical symptoms [2, 7, 10] . Moreover, there are no specific antivirals available against FCV infections and treatment options for FCV-VSD are only limited to supportive therapy.
3	49	52 FCV	Chemical	CHEBI_4974
3	108	111 FCV	Chemical	CHEBI_4974
3	350	360 antivirals	Chemical	CHEBI_22587
3	379	382 FCV	Chemical	CHEBI_4974
3	CHEBI-CHEBI	CHEBI_4974	CHEBI_22587

4|chunk|Several studies have reported different antiviral strategies against FCV [25] [26] [27] [28] [29] . One of the earliest attempts used phosphorodiamidate morpholino oligomers (PMO) to treat cats during three FCV outbreaks (two caused by the FCV-VSD and one linked with a non-lethal FCV pathotype), showing promising results (79.6% vs. 9.7% of cats survived with or without PMO treatment, respectively) [27] .
4	40	49 antiviral	Chemical	CHEBI_22587
4	69	72 FCV	Chemical	CHEBI_4974
4	164	173 oligomers	Chemical	CHEBI_132554
4	207	210 FCV	Chemical	CHEBI_4974
4	281	284 FCV	Chemical	CHEBI_4974
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_4974
4	CHEBI-CHEBI	CHEBI_22587	CHEBI_132554
4	CHEBI-CHEBI	CHEBI_4974	CHEBI_132554

5|chunk|Mefloquine, a human-approved pharmaceutical compound used to prevent or treat malaria, demonstrated an antiviral activity against FCV in vitro at low micromolar concentrations (half maximal effective concentration, EC 50 = 6.03 M), although it demonstrated a poor selectivity index (SI = 3.7). The in vitro combination treatment with mefloquine and recombinant feline interferon- showed only a slight improvement of the IC 50 [26] .
5	0	10 Mefloquine	Chemical	CHEBI_63609
5	29	43 pharmaceutical	Chemical	CHEBI_52217
5	103	112 antiviral	Chemical	CHEBI_22587
5	130	133 FCV	Chemical	CHEBI_4974
5	335	345 mefloquine	Chemical	CHEBI_63609
5	CHEBI-CHEBI	CHEBI_63609	CHEBI_52217
5	CHEBI-CHEBI	CHEBI_63609	CHEBI_22587
5	CHEBI-CHEBI	CHEBI_63609	CHEBI_4974
5	CHEBI-CHEBI	CHEBI_52217	CHEBI_22587
5	CHEBI-CHEBI	CHEBI_52217	CHEBI_4974
5	CHEBI-CHEBI	CHEBI_22587	CHEBI_4974

6|chunk|Another class of compounds tested against FCV includes protease inhibitors (PIs). Synthetic PIs such as GC376 and NPI52 have demonstrated antiviral activity against FCV (EC 50 = 35.2 M and 0.02 M, respectively). They were more effective against FCV when compared to the rhinovirus developmental PI rupintrivir (EC 50 > 50 M) and are considered broad-spectrum compounds showing additional activity against the feline coronavirus and human norovirus [29, 30] .
6	42	45 FCV	Chemical	CHEBI_4974
6	55	74 protease inhibitors	Chemical	CHEBI_37670
6	64	74 inhibitors	Chemical	CHEBI_35222
6	92	95 PIs	Chemical	CHEBI_53232
6	138	147 antiviral	Chemical	CHEBI_22587
6	165	168 FCV	Chemical	CHEBI_4974
6	247	250 FCV	Chemical	CHEBI_4974
6	CHEBI-CHEBI	CHEBI_4974	CHEBI_37670
6	CHEBI-CHEBI	CHEBI_4974	CHEBI_35222
6	CHEBI-CHEBI	CHEBI_4974	CHEBI_53232
6	CHEBI-CHEBI	CHEBI_4974	CHEBI_22587
6	CHEBI-CHEBI	CHEBI_37670	CHEBI_35222
6	CHEBI-CHEBI	CHEBI_37670	CHEBI_53232
6	CHEBI-CHEBI	CHEBI_37670	CHEBI_22587
6	CHEBI-CHEBI	CHEBI_35222	CHEBI_53232
6	CHEBI-CHEBI	CHEBI_35222	CHEBI_22587
6	CHEBI-CHEBI	CHEBI_53232	CHEBI_22587

7|chunk|More recently, fexaramine, a synthetic agonist of the farnesoid X receptor, which plays a role in lipid metabolism, was shown to be effective at blocking FCV entry using in vitro assays, however, a single amino acid change (A539T) in the P2 domain of VP1 (the major capsid protein) was able to confer resistance [25] . In the same study, combination treatment with the aforementioned broad-spectrum PI (NPI52) showed synergistic antiviral activity (synergy log volume of 8.35 M 2 %) and delayed the emergence of virus resistance.
7	39	46 agonist	Chemical	CHEBI_48705
7	90	94 role	Chemical	CHEBI_50906
7	98	103 lipid	Chemical	CHEBI_18059
7	154	157 FCV	Chemical	CHEBI_4974
7	205	210 amino	Chemical	CHEBI_46882
7	205	215 amino acid	Chemical	CHEBI_33704
7	211	215 acid	Chemical	CHEBI_37527
7	273	280 protein	Chemical	CHEBI_16541
7	429	438 antiviral	Chemical	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_50906
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_18059
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_4974
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_46882
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_33704
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_37527
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_16541
7	CHEBI-CHEBI	CHEBI_48705	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_50906	CHEBI_18059
7	CHEBI-CHEBI	CHEBI_50906	CHEBI_4974
7	CHEBI-CHEBI	CHEBI_50906	CHEBI_46882
7	CHEBI-CHEBI	CHEBI_50906	CHEBI_33704
7	CHEBI-CHEBI	CHEBI_50906	CHEBI_37527
7	CHEBI-CHEBI	CHEBI_50906	CHEBI_16541
7	CHEBI-CHEBI	CHEBI_50906	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_18059	CHEBI_4974
7	CHEBI-CHEBI	CHEBI_18059	CHEBI_46882
7	CHEBI-CHEBI	CHEBI_18059	CHEBI_33704
7	CHEBI-CHEBI	CHEBI_18059	CHEBI_37527
7	CHEBI-CHEBI	CHEBI_18059	CHEBI_16541
7	CHEBI-CHEBI	CHEBI_18059	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_4974	CHEBI_46882
7	CHEBI-CHEBI	CHEBI_4974	CHEBI_33704
7	CHEBI-CHEBI	CHEBI_4974	CHEBI_37527
7	CHEBI-CHEBI	CHEBI_4974	CHEBI_16541
7	CHEBI-CHEBI	CHEBI_4974	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_46882	CHEBI_33704
7	CHEBI-CHEBI	CHEBI_46882	CHEBI_37527
7	CHEBI-CHEBI	CHEBI_46882	CHEBI_16541
7	CHEBI-CHEBI	CHEBI_46882	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_33704	CHEBI_37527
7	CHEBI-CHEBI	CHEBI_33704	CHEBI_16541
7	CHEBI-CHEBI	CHEBI_33704	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_37527	CHEBI_16541
7	CHEBI-CHEBI	CHEBI_37527	CHEBI_22587
7	CHEBI-CHEBI	CHEBI_16541	CHEBI_22587

8|chunk|Viral non-structural proteins, such as the protease and the RNA-dependent RNA polymerase (RdRp) are essential for viral replication, and therefore offer attractive antiviral targets. These enzymes lack host homologs, minimizing the chance of off-target effects and have been targeted successfully for the treatment of several viruses, including the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [31, 32] . Using purified recombinant Pro-Pol, we established two in vitro assays for the screening of new FCV antiviral compounds. Representative nucleoside analogues (NAs), non-nucleoside inhibitors (NNIs), PIs, and the broad-spectrum nitazoxanide, were tested for FCV antiviral activity using both in vitro enzyme and cell culture-based methods. Here we identify two antiviral agents as potential therapeutic options for the FCV infection.
8	74	77 RNA	Chemical	CHEBI_33697
8	164	173 antiviral	Chemical	CHEBI_22587
8	519	522 FCV	Chemical	CHEBI_4974
8	523	532 antiviral	Chemical	CHEBI_22587
8	559	569 nucleoside	Chemical	CHEBI_33838
8	559	579 nucleoside analogues	Chemical	CHEBI_60783
8	602	612 inhibitors	Chemical	CHEBI_35222
8	679	682 FCV	Chemical	CHEBI_4974
8	683	692 antiviral	Chemical	CHEBI_22587
8	782	791 antiviral	Chemical	CHEBI_22587
8	782	798 antiviral agents	Chemical	CHEBI_22587
8	840	843 FCV	Chemical	CHEBI_4974
8	CHEBI-CHEBI	CHEBI_33697	CHEBI_22587
8	CHEBI-CHEBI	CHEBI_33697	CHEBI_4974
8	CHEBI-CHEBI	CHEBI_33697	CHEBI_33838
8	CHEBI-CHEBI	CHEBI_33697	CHEBI_60783
8	CHEBI-CHEBI	CHEBI_33697	CHEBI_35222
8	CHEBI-CHEBI	CHEBI_22587	CHEBI_4974
8	CHEBI-CHEBI	CHEBI_22587	CHEBI_33838
8	CHEBI-CHEBI	CHEBI_22587	CHEBI_60783
8	CHEBI-CHEBI	CHEBI_22587	CHEBI_35222
8	CHEBI-CHEBI	CHEBI_4974	CHEBI_33838
8	CHEBI-CHEBI	CHEBI_4974	CHEBI_60783
8	CHEBI-CHEBI	CHEBI_4974	CHEBI_35222
8	CHEBI-CHEBI	CHEBI_33838	CHEBI_60783
8	CHEBI-CHEBI	CHEBI_33838	CHEBI_35222
8	CHEBI-CHEBI	CHEBI_60783	CHEBI_35222

